Latest Articles

Publication Date
UCLA alumnus’s pioneering endometriosis treatment plans to enter clinical trials - Daily Bruin

UCLA alumnus’s pioneering endometriosis treatment plans to enter clinical trials Daily Bruin

Published: June 18, 2026, 4:55 p.m.
SGLT2 Inhibition as a Novel Therapeutic Strategy in Rheumatic Heart Disease.

Rheumatic heart disease (RHD) remains a major cause of cardiovascular morbidity and premature mortality among children and young adults, particularly in low- and middle-income countries. Current management relies on antibiotic …

Published: June 4, 2026, midnight
The Microbiota-Endometriosis Axis: An Immune-Endocrine Integration Model and Emerging Therapeutic Targets.

Endometriosis is a chronic, estrogen-dependent inflammatory disorder characterized by the ectopic implantation and persistence of endometrial-like tissue outside the uterine cavity. Despite its high prevalence and significant impact on quality …

Published: May 28, 2026, midnight
Pfizer targets VEGF bispecific white space | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Pfizer targets VEGF bispecific white space | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Published: May 21, 2026, 12:46 p.m.
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial - Clinical Trials Arena

MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial Clinical Trials Arena

Published: May 18, 2026, 4:34 p.m.
Emerging Clinical Trials and Future Therapeutic Strategies in Recurrent Endometrial Cancer - OncLive

Emerging Clinical Trials and Future Therapeutic Strategies in Recurrent Endometrial Cancer OncLive

Published: May 14, 2026, 12:06 a.m.
FGFR2-responsive self-assembled hydrogel releases its inhibitor to suppress the progression of endometriosis.

Fibroblast growth factor receptor 2 (FGFR2) has emerged as a highly promising therapeutic target due to its critical role in the pathogenesis and progression of endometriosis. To date, a variety …

Published: May 9, 2026, midnight
Terazosin as a Non-Hormonal Treatment for Endometriosis.

Endometriosis is a chronic, estrogen-dependent inflammatory disease including aberrant local steroidogenesis, inflammation, angiogenesis, oxidative stress, and prostaglandin-mediated pain. Given the elevated adrenergic receptor expression in endometriotic lesions and the potential …

Published: May 2, 2026, midnight
SGO 2026 – GSK bucks the B7-H4 trend | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

SGO 2026 – GSK bucks the B7-H4 trend | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Published: April 13, 2026, 12:32 p.m.
SGO 2026 – BioNTech’s Enhertu me-too comes up short | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

SGO 2026 – BioNTech’s Enhertu me-too comes up short | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Published: April 13, 2026, 10:30 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!